Insufficiency fractures are beginning to emerge in case reports of patients on long-term bisphosphonate therapy. The side effects associated with the long-term use of bisphosphonates were once thought to only involve renal and gastrointestinal (GI) toxicity and osteonecrosis of the jaw, but it is becoming clear that the very condition bisphosphonates were meant to treat could be causing another, trading insufficiency fractures for another type of insufficiency fracture. We review the literature concerning this surprising trend in addition to providing 2 case reports and conclude that these fractures do occur, that they can heal uneventfully, and that further research is needed to determine optimum treatment algorithms concerning duration of treatment and to weigh the potential benefits and morbidity of bisphosphonate treatment.
Introduction
Insufficiency fractures are beginning to emerge in case reports of patients on long-term bisphosphonate therapy. The side effects associated with the long-term use of bisphosphonates were once thought to only involve renal and gastrointestinal (GI) toxicity and osteonecrosis of the jaw, but it is becoming clear that the very condition bisphosphonates were meant to treat could be causing another, trading insufficiency fractures for another type of insufficiency fracture. We review the literature concerning this surprising trend in addition to providing 2 case reports.
Case 1
We present the case of a 63-year-old female with a subtrochanteric femur insufficiency fracture likely secondary to long-term bisphosphonate therapy. She presented to our clinic on referral from her oncologist after her chronic right proximal thigh pain became acute and stopped her continuing as a community ambulatory. Despite this, she stayed active, walking with a cane in the house and using a wheelchair for longer distances.
The patient was under treatment for metastatic breast cancer with chemotherapy and a 10-year course of monthly intravenous bisphosphonate therapy; otherwise, she was without any major medical problems. She had never previously sustained an insufficiency fracture of any kind.
She previously smoked, but quit many years ago, and did not drink alcohol. She experienced a normal course with respect to menarche and menopause and did not undergo hysterectomy or estrogen treatment.
On physical examination, she was a 5 feet, 2-inch, 112 lb 63-year-old caucasian female with a pale complexion. She had tenderness of the right proximal thigh without contusion or other surface abnormality. Prior to presentation, she could stand and walked with an antalgic gait and tripronged cane assistance, however, subsequently was unable to ambulate. She had normal sensation and vascular flow to the lower extremities. She demonstrated slight weakness of the right hip flexor, quadriceps, and hamstring muscles.
In Figure 1 , radiographs of the pelvis and right femur showed a displaced, varus angulated, femur fracture 1.5 cm distal to the lesser trochanter. There was no evidence of pathologic change within the medullary or cortical bone of the femur, neither blastic nor lytic.
We discussed all treatment options with the patient and her family including nonoperative care and surgical repair. We elected to cease her bisphosphonate therapy, and after obtaining medical clearance the patient elected to undergo cephalomedullary nailing of her right femur ( Figure 2 ). Her postoperative course was uneventful and she returned to community 1 University of Florida-Jacksonville, Department of Orthopaedics ambulatory status within 6 weeks from surgery. Specimens taken from the fracture site as well as examination of the reamings from the fractured femur showed no evidence of metastatic carcinoma, only reactive bone. There was clear evidence of bony healing of the fracture at 12 weeks' follow-up ( Figure 3 ).
Case 2
A second case was a 64-year-old female with a history of systemic lupus erythematosus for which she was not on chronic steroids, fibromyalgia, hypothyroidism, and osteoporosis presented with bilateral subtrochanteric insufficiency femur fractures likely secondary to long-term bisphosphonate therapy. In addition to her aforementioned chronic medical problems, she was noted to have a hysterectomy in her early 30s secondary to endometriosis after which she was placed on estrogen replacement therapy. For more than 10 years prior to presentation, she was treated with ongoing, weekly bisphosphonate treatment with vitamin D supplementation. She had never previously sustained an insufficiency fracture of any kind, she previously smoked, but quit many years ago, and did not drink alcohol.
On initial presentation, the patient presented with pain in her right groin after fall from standing height. Physical examination revealed she was a 5 feet, 1-inch, 176 lb 64-year-old caucasian woman. She had tenderness of the right proximal thigh without contusion or other surface abnormality. She could not ambulate on that lower extremity. She had normal sensation and vascular flow to the lower extremities. Radiographs of the pelvis and right femur showed a displaced, varus angulated, femur fracture 1 cm distal to the lesser trochanter. There was no evidence of pathologic change within the medullary or cortical bone of the femur, neither blastic nor lytic.
We discussed all treatment options with the patient and her family including nonoperative care and surgical repair. We elected to cease her bisphosphonate therapy, and after obtaining medical clearance the patient elected to undergo cephalomedullary nailing of her right femur. Her postoperative course up to her 3-month follow-up was uneventful, and she returned to community ambulatory status within 6 weeks from surgery. Specimens taken from the fracture site as well as examination of the reamings from the fractured femur showed no evidence of metastatic carcinoma, only reactive bone. There was clear evidence of bony healing of the fracture at 12 weeks' follow-up.
At about 6 months postoperatively, she noted increasing pain in the contralateral, left hip ( Figure 4 ). This hip pain was initially not divulged, but rather attributed to her normal daily pains associated with her fibromyalgia. She had a 2-month period of increasing pain in her left hip that prohibited her from walking, and she was subsequently evaluated and diagnosed with another insufficiency fracture on her contralateral subtrochanteric femur. She had no trauma associated with this fracture.
The patient was evaluated and treated at an outside institution, and radiographs of the pelvis and left femur showed a displaced femur fracture just distal to the lesser trochanter ( Figure  5 ). There was no evidence of pathologic change within the medullary or cortical bone of the femur, neither blastic nor lytic. She underwent cephalomedullary nailing of her left femur with subsequent follow-up at 3 months, demonstrating healing about her fracture site ( Figure 6 ). She was also able to return to community ambulatory status with only complaints of trochanteric bursitis of her left hip.
Discussion
Insufficiency fractures are not rare, accounting for 700 000 fractures yearly in the United States, including 10 to 30 per 1000 involving the axial skeleton in women over 50 years of age. 1 As defined by the World Health Organization, osteoporosis, a major contributor to axial and appendicular insufficiency fractures, is a bone mineral density (BMD) greater than 2.5 standard deviations below the peak 1 mass of a young adult. Bone mass peaks between the ages of 16 and 25 years and decreases with aging due to multifactorial influences. 2 Regulation of bone homeostasis, balancing bone formation and resorption, is under the control of direct mechanical loading as well as endogenous hormonal influences. Interleukin (IL) 1, IL-6, tumor necrosis factor (TNF)-a, calcitonin, and prostaglandin E2 regulate osteoclasts directly, while parathyroid hormone (PTH) and vitamin D influence osteoblasts which in turn affect osteoclastic bone resorption. With aging, however, this balance breaks down leading to weakened bone more susceptible to fracture. 3 As one advances in age, physical activity decreases, and bone is no longer mechanically loaded as it once was. Because form follows function according to Wolff's law, bone is no longer formed by osteoblasts when it is not subjected to stresses. In addition to inactivity, a myriad of other factors influence the development of osteoporosis. Lack of exposure to sunlight, inadequate vitamin D intake, decreased dietary consumption and or absorption of calcium, alcohol and tobacco usage, parathyroid and thyroid hormones excess, and decreased levels of estrogen in women all cause decreases in bone mass. Together, these combined cause weakened bone structure.
The entirety of a person's bone mass is replaced about every 4 years in children to every 20 years in adults. This turnover is important; however it slows with aging due to the aforementioned factors. The decrease in bone mass seen with advancing age, osteoporosis, and osteopenia affects trabecular bone to a greater degree than cortical bone. This phenomenon occurs because trabecular bone turns over at a rate of 8 times that of cortical bone due to its increased surface area. Therefore, vertebral compression fractures and metaphyseal fractures are more likely to occur due to the high degree of trabecular bone compared with cortical bone. 3 In order to combat the effects of decreasing bone mass, bisphosphonates and other treatments have been employed to slow the progressive loses. Bisphosphonates work to prevent fracture in susceptible patients by slowing the osetoclastic resorption of bone and therefore tipping bone homeostasis toward increased BMD. They have been shown to decrease the risk of axial and appendicular skeletal fracture in osteoporotic patients and their ability to decrease skeletal morbidity as an adjunct to breast cancer antineoplastic therapy has been well described. As a palliative measure, bisphosphonates, when compared to placebo or the absence of bisphoshonate therapy, reduce the time to, the risk of, and the rate of skeletal events. As bisphosphonates decrease osteoclastic resorption, there is no increase in osteoid being made. Simply, the older bone continues to be mineralized, thus increasing BMD and improving bone densitometry scores. This also, initially prevents fractures. There may be, however, a point where it becomes ''too much of a good thing.'' Initially, Odivna reported 9 cases of fractures in patients undergoing long-term intravenous bisphosphonate therapy. 4 The fractures reported in this report were all noted to be atraumatic and nonspinal in nature, while 6 of the 9 patients were noted to have delayed or absent fracture healing during bisphosphonate treatment. Theoretically, the decreased osteoclastic resorption taxes long-term bone remodeling resulting in a more highly mineralized however possibly more brittle bone at some undetermined point during long-term bisphosphonate therapy. In addition, with retarded remodeling, microdamage to the trabeculae goes unrepaired. In high-stress areas, this obviously could sum to larger cracks and eventually complete fractures. This theoretical state resembles the pathologic process of osteopetrosis-for which an affected patient develops underremodeled, heavily cortical bones that are ironically weak, and at an increased risk of insufficiency fracture. This theoretical morbidity of long-term bisphosphonate therapy was first seen with patients treated for Pagets disease and more recently by Goh et al in patients on long-term bisphosphonate therapy for documented osteoporosis. 5 In Goh et al's study, 5 13 patients were selected who sustained low-energy subtrochanteric fractures in Singapore. Of the 13 patients studied, all were women, and 9 were found to be on long-term bisphosphonate therapy. The patients noted to be on bisphosphonates were noted to be of younger age than the group not on bisphosphonates and were noted to have prodromal pain prior to fracture. They concluded that the interference of bone turnover may predispose individuals to low-energy fracture. An expansion of this study was performed by Kwek et al in 2008 who, in addition to the 9 patients in Goh et al's study on long-term bisphosphonate therapy, retrospectively reviewed additional records to find an additional 8 patients with similar low-energy fracture patterns while on long-term bisphosphonates. 6 A similar conclusion was also drawn from this study. There is also animal model research that has shown high-dose bisphosphonates may weaken rat femurs. Although our patient went on to uneventful healing, the consequence of long-term decreased bony remodeling has been described to decrease the healing rate of some insufficiency fractures.
In addition to the patients in Goh and Kwek's studies, 5, 6 Sayed-Noor 7 also submitted a case report detailing an insufficiency fracture in a 72-year-old female undergoing long-term bisphosphonate treatment, and Neviaser et al performed a retrospective review on low-energy femur fractures. 8 A total of 70 patients fit the criteria of having sustained a low-energy femur fracture, while 25 of those patients were noted to currently being treated with bisphosphonates. Of those 25 patients, 19 patients demonstrated a characteristic simple transverse fracture in the subtrochanteric region with unicortical beaking in an area of hypertrophy that was only seen in 1 other patient not on bisphosphonate therapy. In response to the realization that insufficiency fractures may be caused by the therapy that is initially protective, Ott has suggested a 5-year cap on the safe length of treatment for bisphosphonate therapy and suggests those remaining at high risk of fracture or continued fracture in spite of bisphosphonate therapy may benefit from pulsed PTH or an alternate, as of yet undetermined, intermittent dosing schedule of bisphosphonates. 9 As this is an emerging concept, there are no clinical trials to guide our protocol. In our case, we elected to stop bisphosphonate therapy and observe.
In conclusion, we present 2 cases of subtrochanteric femur insufficiency fractures likely resultant of long-term intravenous bisphosphonate therapy. We do so to submit that these fractures do occur and that they can heal uneventfully. Whether cessation of bisphosphonate therapy is needed to assure healing cannot be stated from these 2 cases or the limited number of cases reported in the literature. It does underline the need for further collection of these cases and further research into the potential morbidity of long-term bisphosphonate therapy-a highly effective treatment of a very prevalent condition.
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